NCT04218695View on ClinicalTrials.gov

Prophylactic Antibiotics in Admitted Cirrhotics

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

August 28, 2021

Conditions
Cirrhosis, Liver
Interventions
DRUG

Ceftriaxone

Antibiotic

DRUG

Normal saline

50cc intravenous once daily

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

American Association for the Study of Liver Diseases

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04218695 - Prophylactic Antibiotics in Admitted Cirrhotics | Biotech Hunter | Biotech Hunter